drugset / Trial / NCT00774072

Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

NCT00774072

Phase 2 Completed 9 enrolled University of Jena
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether the nasal inhalation of Gernebcin® is effective to decrease the Pseudomonas aeruginosa bacterial count in the nasal lavage fluid.

Timeline

Start
2008-10
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tobramycin Small molecule 80 mg Inhaled